European Industry Backs Biosimilars ‘Scorecards’
Ratings Provide Analyses Of Biosimilar Policies In 12 Countries
Medicines for Europe and IQVIA have partnered to test biosimilar sustainability in 12 European countries by issuing scorecards that measure the contribution of a country’s biosimilar policies to health systems.
You may also be interested in...
European policy makers must act quickly to harness the benefits of biosimilars as part of the new EU Pharma Strategy, Medicines for Europe insists in the wake of the latest annual report on European biosimilar competition.
Sandoz’ global head of biopharmaceuticals says that in the context of COVID-19, biosimilars can play a key role to increase access and unlock savings that can be invested in innovation to support “the long-term sustainability of healthcare systems.”
Japan’s Nippon Chemiphar has managed to reduce its rate of decline in pharmaceutical sales in the third quarter of FY21, on the back of well-performing recently-launched generics and group-wide structural reforms and cost reductions. The company is making no changes to its full-year forecast.